You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
IFR:箕星藥業考慮明年在香港上市,籌集約3億美元

據彭博報道,IFR援引未具名知情人士報道,箕星藥業正在考慮於2022年在香港IPO,籌集約3億美元,公司正在與財務顧問就上市計劃進行磋商。

箕星藥業針對重大疾病和危及生命的疾病開發世界一流的治療方法。目前,箕星藥業的主導項目是由Cytokinetics公司授權的用於臨牀治療肥厚型心肌病的新型口服小分子心肌肌球蛋白抑制劑(CK-274)。

公司由RTW Investments(RTW)投資創立,RTW是一家總部位於紐約的全球性全生命週期投資公司,專注於發掘生物製藥和醫療技術的變革性和顛覆性創新。

2021年7月,箕星藥業宣佈完成來自RTW投資的B輪融資,這筆新資金將助力箕星實現對合作夥伴的承諾以及提供公司運營支持。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account